Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
EDSA: Something big may be transpiring with the HOMEBOYS at this Firm!!!
Took off on offering news .. $3.11 + 60%
Nobody watches this stock and that's a mistake. 12 month minimum for full data analysis but we can get the interim data analysis much sooner. There was 125 patients enrolled in the Canadian P3 and that was 2 years ago. Recently, the Canadian P3 and the US P3 have been harmonized and the patient protocol has been changed to 600 total patients from the original 800. We could be closer than we think. Upon that data, the shares will double or triple, if I were Par, I would apply for EUA and the shares will rocket even further. He can then do an offering at a much higher valuation, and start the P2 Vitligo CXL-10, and EBO5 Fibrosis trials.
Wonder what mm are doing - 35 min volatility halt is definitely longer than normal
Chop chop as high as $1.08 has a variety of resistance levels and has a phase 3 in works
EDSA: Hey, big THANKS to ya, Capt. S-L!!!
And, by the way, GO-GO-GO-EDSA=$$$$$$
Hey my brother I feel great that you are cleaning up :) Hey EDSA gained again today. Feeling a nice play in the near future .
EDSA: Hey, & YOU'RE stock picks, Sir, have been a "blessing" --- to my BANK account balances, Bro!!!
$2,26 close so that dip last week was a Godsend
Once the volume picks up, we will have a classic run., :)
$2.25 and looiking up! LOL
POP @ $2.14 up 23% LMAO. :)
EDSA; YEP!!! That's how the SMART players do this. (Not sure if I qualify, though.)
watching for poss re entry here.
EDSA: Hey, I hear-ya on THAT note, 'S-S' Dude!! (EDSA up a pinch, as I write this.)
Geeze dude, I hope that got prepared you don't wanna be in the middle of the Pacific ocean and have that happen EDSA is a baby for keepers
EDSA: Yep!! it sure is, Dude!!! (Sorry for this rather BELATED response, Bro!! Big BOAT issues over here in my San Diego; a LEAK!)
Is this a beautiful stock or what! 2023 will be double digs. Hope you had a nice holiday weekend bro.
its trying, but manipulation is king for now.
this is trying to bust out in pre …
…
market but the manipulation is holding it back, for now. lets do this!
this is trying to bust out in pre …
…
market but the manipulation is holding it back, for now. lets do this!
yup, see ya in the morning!
Glad to see everyone here is making money. I've notice my post are being deleted
reena969
Re: A deleted message
Tuesday, December 20, 2022 10:22:09 AM
I missed that one Watching EDSA low float ,so many on my scanner
I loaded @.9744 .
I guess it's time for me to keep quite and just make money. Happy Trading everyone.
grabbed some on this dip! hi all
.$2.64 HOD :)
What a beautiful ask. @ $2.30
Now she has gate speed!!!!!!!!!!!!!!!!!!!!
She is a keeper bro! :)
$EDSA: OHhhhhhhh yaaaaaaaaaa... just another GREAT DAY, now $2
How about that run, right ???
$TMNA is next
GO $EDSA
Nice!!!!!!!!!!!!!!!
$EDSA: Gettin a 2nd day boost here............
just tapped 1.30
Thats not too baddddddddddd
GO $EDSA
Been holding this one. It's got great potential and an excellent buy and hold.
$EDSA : FastTrack FDA ARDS Drug Candidate
Could get more boost today.
Now up to $1.10
GO $EDSA
Edesa Biotech announced final results from the Phase 2 portion of its ongoing Phase 2/Phase 3 clinical study. This study is evaluating the company’s monoclonal antibody candidate, EB05, as a single-dose treatment for hospitalized patients with or at risk of developing Covid-19 induced Acute Respiratory Distress Syndrome (ARDS). The company previously reported initial topline data provided by the study’s data safety monitoring board, which preemptively unblinded certain study data for efficacy signals. Edesa has now completed a formal Clinical Study Report (CSR) for U.S. regulators on the full, validated Phase 2 dataset.
Trial results: In the final Phase 2 clinical trial results, Edesa reported that EB05 demonstrated a statistically significant and clinically meaningful trend for mortality and survival time for all randomized subjects in the critically ill cohort (the intent to treat, or ITT, population). Today, the company reported a revised 28-day death rate of 7.7% in the EB05 plus standard of care (SOC) arm versus 40% in the placebo + SOC arm in critically severe patients on ECMO therapy (extracorporeal membrane oxygenation) or Invasive Mechanical Ventilation (IMV) plus organ support with ARDS at baseline (p=0.04). The revised Survival Analysis using Cox’s Proportional Hazard Model demonstrated that patients treated with EB05 plus SOC had an 84.0% reduction in the risk of dying when compared to placebo + SOC at 28 days.
EDSA mentioned and the company of course does not tell anything to investors.. Imo this is important and the stock will fly when the market turns or the company will put out great news
https://magazine.utoronto.ca/research-ideas/health/preventing-the-next-pandemic-emerging-and-pandemic-infections-consortium-epic/
Followers
|
26
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
517
|
Created
|
06/23/16
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |